[en] Introduction: Brain distribution of synaptic vesicle protein 2Awas measured with fluorine-18 UCBH ([18F]UCB-H) and positron emission tomography (PET).
Methods: Images of synaptic density were acquired in healthy volunteers (two young participants and two seniors). Input function was measured by arterial blood sampling (arterial input function) and derived from PET images using carotid activity (image-derived input function). Logan graphical analysis was used to estimate regional synaptic vesicle protein 2A distribution volume.
Results: [18F]UCB-H uptake was ubiquitous in cortical and subcortical gray matter. Arterial input function and image-derived input function provided regional distribution volume with a high linear relationship.
Discussion: The cerebral distribution of [18F]UCB-H is similar to that recently observed with carbon-11 UCB-J ([11C]UCB-J). An accurate [18F]UCB-H quantification can be performed without invasive arterial blood sampling when no suitable reference region is available, using dynamic PET carotid activity. Brain synaptic density can be studied in vivo in normal and pathological aging.
Research center :
GIGA CRC (Cyclotron Research Center) In vivo Imaging-Aging & Memory - ULiège
Disciplines :
Radiology, nuclear medicine & imaging
Author, co-author :
Bahri, Mohamed Ali ; Université de Liège > Centre de recherches du cyclotron > Centre de recherches du cyclotron
Plenevaux, Alain ; Université de Liège > Département de chimie (sciences) > Département de chimie (sciences)
Aerts, Joël ; Université de Liège > Département de pharmacie > Département de pharmacie
Bastin, Christine ; Université de Liège > Département des sciences cliniques > Neuroimagerie des troubles de la mémoire et révalid. cogn.
Becker, Guillaume ; Université de Liège > Centre de recherches du cyclotron
Mercier, Joël
Valade, Anne
Buchanan, Tim
Mestdagh, Nathalie
LEDOUX, Didier ; Centre Hospitalier Universitaire de Liège - CHU > Service des soins intensifs généraux
Seret, Alain ; Université de Liège > Département de physique > Imagerie médicale expérimentale
Luxen, André ; Université de Liège > Département de chimie (sciences) > Laboratoire de chimie organique de synthèse
Salmon, Eric ; Université de Liège > Département des sciences cliniques > Neuroimagerie des troubles de la mémoire et révalid. cogn.
Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8 (2012), 1–13.
Spires-Jones, T.L., Hyman, B., The Intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 82 (2014), 756–771.
Pozueta, J., Lefort, R., Shelanski, M.L., Synaptic changes in Alzheimer's disease and its models. Neuroscience 251 (2013), 51–65.
Mendoza-Torreblanca, J.G., Vanoye-Carlo, A., Phillips-Farfán, B.V., Carmona-Aparicio, L., Gómez-Lira, G., Synaptic vesicle protein 2A: Basic facts and role in synaptic function. Eur J Neurosci 38 (2013), 3529–3539.
Lynch, B.A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S.M., Matagne, A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101 (2004), 9861–9866.
Robinson, J.L., Molina-Porcel, L., Corrada, M.M., Raible, K., Lee, E.B., Lee, V.M., et al. Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. Brain 137 (2014), 2578–2587.
Sanchez, P.E., Zhu, L., Verret, L., Vossel, K.A., Orr, A.G., Cirrito, J.R., et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci 109 (2012), E2895–E2903.
Bakker, A., Krauss, G.L., Albert, M.S., Speck, C.L., Jones, L.R., Stark, C.E., et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74 (2012), 467–474.
Mercier, J., Archen, L., Bollu, V., Carré, S., Evrard, Y., Jnoff, E., et al. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. ChemMedChem 9 (2014), 693–698.
Warnock, G.I., Aerts, J., Bahri, M.A., Bretin, F., Lemaire, C., Giacomelli, F., et al. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain. J Nucl Med 55 (2014), 1336–1342.
Bretin, F., Warnock, G., Bahri, M.A., Aerts, J., Mestdagh, N., Buchanan, T., et al. Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. EJNMMI Res, 3, 2013, 35.
Bretin, F., Bahri, M.A., Bernard, C., Warnock, G., Aerts, J., Mestdagh, N., et al. Biodistribution and radiation dosimetry for the novel SV2A radiotracer [18 F]UCB-H: first-in-human study. Mol Imaging Biol 17 (2015), 557–564.
Finnema, S.J., Nabulsi, N.B., Eid, T., Detyniecki, K., Lin, S.F., Chen, M.K., et al. Imaging synaptic density in the living human brain. Sci Transl Med, 8, 2016, 348ra96.
Schain, M., Benjaminsson, S., Varnäs, K., Forsberg, A., Halldin, C., Lansner, A., et al. Arterial input function derived from pairwise correlations between PET-image voxels. J Cereb Blood Flow Metab 33 (2013), 1058–1065.
Lammertsma, A.A., Hume, S.P., Simplified reference tissue model for PET receptor studies. Neuroimage 4 (1996), 153–158.
Becker, G., Warnier, C., Serrano, M.E., Bahri, M.A., Mercier, J., Lemaire, C., et al. Pharmacokinetic Characterization of [18F]UCB-H PET Radiopharmaceutical in the Rat Brain. Mol Pharm 14 (2017), 2719–2725.
Brun, A., Englund, E., A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann Neurol 19 (1986), 253–262.
Rieckmann, A., Van Dijk, K.R., Sperling, R.A., Johnson, K.A., Buckner, R.L., Hedden, T., Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. Neurobiol Aging 42 (2016), 177–188.